{"id":"chemotherapy-pembrolizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Myelosuppression (anemia, neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL3137343","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination leverages two complementary approaches: cytotoxic chemotherapy directly damages cancer cell DNA and triggers cell death, while pembrolizumab, a PD-1 inhibitor, removes immune checkpoint inhibition to allow T cells to recognize and attack tumor cells. The chemotherapy-induced tumor cell death can also release tumor-associated antigens that prime immune responses, potentially synergizing with pembrolizumab's immunostimulatory effects.","oneSentence":"Chemotherapy kills rapidly dividing cancer cells while pembrolizumab blocks PD-1 to enhance immune recognition and destruction of remaining tumor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:55.473Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic non-small cell lung cancer"},{"name":"Other solid tumors (specific indications depend on chemotherapy backbone used)"}]},"trialDetails":[{"nctId":"NCT06225596","phase":"PHASE2, PHASE3","title":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","status":"RECRUITING","sponsor":"BicycleTx Limited","startDate":"2024-01-24","conditions":"Metastatic Urothelial Cancer","enrollment":956},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT07198074","phase":"PHASE3","title":"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-01-27","conditions":"Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma","enrollment":255},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT06422806","phase":"PHASE3","title":"Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-11","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","enrollment":365},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":"Advanced or Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":188},{"nctId":"NCT03914612","phase":"PHASE3","title":"Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma","enrollment":813},{"nctId":"NCT02954874","phase":"PHASE3","title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-18","conditions":"Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7","enrollment":1155},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT06627647","phase":"PHASE3","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-11-27","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":878},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT05673200","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-25","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT06096844","phase":"PHASE3","title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-19","conditions":"Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8","enrollment":304},{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":"Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":1210},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT05555732","phase":"PHASE3","title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2023-01-11","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":1170},{"nctId":"NCT06119581","phase":"PHASE3","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-12-21","conditions":"Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis","enrollment":1264},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT04216316","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-14","conditions":"Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":12},{"nctId":"NCT04858269","phase":"PHASE2","title":"First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-27","conditions":"Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma","enrollment":32},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT04003636","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-24","conditions":"Biliary Tract Carcinoma","enrollment":1069},{"nctId":"NCT03288545","phase":"PHASE1, PHASE2","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-10-11","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms","enrollment":348},{"nctId":"NCT06917079","phase":"PHASE1","title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2025-03-31","conditions":"Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":387},{"nctId":"NCT07486817","phase":"PHASE2","title":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-05-08","conditions":"Lung Cancer, Non-squamous, Non-small Cell","enrollment":60},{"nctId":"NCT05911295","phase":"PHASE3","title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2023-09-22","conditions":"Urothelial Carcinoma","enrollment":412},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT05027633","phase":"PHASE2","title":"Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-11-02","conditions":"Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses","enrollment":35},{"nctId":"NCT06831955","phase":"PHASE2","title":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-02-01","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting","enrollment":356},{"nctId":"NCT07486687","phase":"PHASE3","title":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2026-04","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer","enrollment":1000},{"nctId":"NCT07190248","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":675},{"nctId":"NCT07485179","phase":"","title":"Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-03-12","conditions":"Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":770},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT03390504","phase":"PHASE3","title":"A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-23","conditions":"Urothelial Cancer","enrollment":629},{"nctId":"NCT05789082","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-06-20","conditions":"Non-Small Cell Lung Cancer","enrollment":320},{"nctId":"NCT04430699","phase":"PHASE2","title":"Cisplatin+Pembrolizumab+RT in Vulvar Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-29","conditions":"Vulvar Cancer, Vulvar Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT04253964","phase":"PHASE2","title":"Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-07-01","conditions":"Nonsmall Cell Lung Cancer, Performance Status","enrollment":105},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT06151574","phase":"PHASE3","title":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-02-09","conditions":"Lung Cancer, Non-squamous, Non-small Cell","enrollment":416},{"nctId":"NCT06726265","phase":"PHASE3","title":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immutep S.A.S.","startDate":"2025-03-21","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":756},{"nctId":"NCT05422794","phase":"PHASE1","title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-18","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma","enrollment":57},{"nctId":"NCT02818920","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab","status":"COMPLETED","sponsor":"Neal Ready MD PhD","startDate":"2017-01","conditions":"Non-small Cell Lung Carcinoma","enrollment":35},{"nctId":"NCT07063745","phase":"PHASE2, PHASE3","title":"A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-01-02","conditions":"Metastatic Non-small Cell Lung Cancer With MTAP Deletion","enrollment":590},{"nctId":"NCT06712316","phase":"PHASE2, PHASE3","title":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-01-07","conditions":"Non-small Cell Lung Cancer","enrollment":1260},{"nctId":"NCT05984277","phase":"PHASE3","title":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-10-24","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":1200},{"nctId":"NCT02998268","phase":"PHASE2","title":"Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2017-03-07","conditions":"Esophageal Adenocarcinoma","enrollment":42},{"nctId":"NCT06731478","phase":"PHASE3","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-02-27","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":726},{"nctId":"NCT03486873","phase":"PHASE3","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-08-21","conditions":"Solid Tumors, Hematologic Malignancies","enrollment":3500},{"nctId":"NCT06469944","phase":"PHASE1, PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":160},{"nctId":"NCT04165070","phase":"PHASE1, PHASE2","title":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":450},{"nctId":"NCT07468838","phase":"","title":"Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2026-05","conditions":"Prostate Cancer, Bladder Cancer","enrollment":25},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT04165798","phase":"","title":"KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1065},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT03360890","phase":"PHASE2","title":"Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2018-03-26","conditions":"Thyroid Cancer, Salivary Gland Cancer","enrollment":46},{"nctId":"NCT06875310","phase":"PHASE3","title":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)","status":"RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2025-04-24","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":630},{"nctId":"NCT06173505","phase":"PHASE1, PHASE2","title":"Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC","status":"TERMINATED","sponsor":"Xencor, Inc.","startDate":"2023-12-27","conditions":"Nonsquamous Non-small Cell Lung Cancer","enrollment":28},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT05687266","phase":"PHASE3","title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-29","conditions":"NSCLC","enrollment":1350},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06731413","phase":"PHASE2","title":"Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-02-11","conditions":"Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT05410145","phase":"PHASE1, PHASE2","title":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"D3 Bio (Wuxi) Co., Ltd","startDate":"2022-08-03","conditions":"KRAS P.G12C","enrollment":442},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT06635824","phase":"PHASE3","title":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2024-11-25","conditions":"PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC","enrollment":191},{"nctId":"NCT06687369","phase":"PHASE3","title":"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)","status":"RECRUITING","sponsor":"mAbxience Research S.L.","startDate":"2024-12-30","conditions":"Non Squamous Non Small Cell Lung Cancer","enrollment":726},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT04093167","phase":"PHASE2, PHASE3","title":"Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2020-05-26","conditions":"Lung Cancer","enrollment":230},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT02402920","phase":"PHASE1","title":"Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-22","conditions":"Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm","enrollment":83},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT07020221","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","status":"RECRUITING","sponsor":"Verastem, Inc.","startDate":"2025-06-24","conditions":"Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer","enrollment":295},{"nctId":"NCT04030455","phase":"PHASE2","title":"Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-07","conditions":"Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8","enrollment":28},{"nctId":"NCT06162221","phase":"PHASE1, PHASE2","title":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-01-18","conditions":"Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer","enrollment":616},{"nctId":"NCT04736173","phase":"PHASE2","title":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2021-02-08","conditions":"Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer","enrollment":169},{"nctId":"NCT06764875","phase":"PHASE3","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-01","conditions":"HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":840},{"nctId":"NCT07455019","phase":"PHASE2","title":"A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-05-01","conditions":"Esophageal Cancer","enrollment":28},{"nctId":"NCT06430866","phase":"PHASE3","title":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-09-12","conditions":"Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)","enrollment":154},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT04262466","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunocore Ltd","startDate":"2020-02-25","conditions":"Select Advanced Solid Tumors","enrollment":410},{"nctId":"NCT04222972","phase":"PHASE3","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-24","conditions":"RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung","enrollment":223},{"nctId":"NCT05934448","phase":"PHASE2","title":"Pembro Plus CAR T-cell Therapy in R/R in PMBCL","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-11-15","conditions":"Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory","enrollment":35},{"nctId":"NCT05721755","phase":"PHASE3","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-06-08","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":290},{"nctId":"NCT03969446","phase":"PHASE1","title":"Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-05-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT06561386","phase":"PHASE3","title":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-10-07","conditions":"Non-small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT05812807","phase":"PHASE3","title":"Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-06-14","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":1295},{"nctId":"NCT03313778","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2017-08-14","conditions":"Solid Tumors","enrollment":161},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":62,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Carbo-paclitaxel/ nab-paclitaxel"],"phase":"marketed","status":"active","brandName":"Chemotherapy+Pembrolizumab.","genericName":"Chemotherapy+Pembrolizumab.","companyName":"Tang-Du Hospital","companyId":"tang-du-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chemotherapy kills rapidly dividing cancer cells while pembrolizumab blocks PD-1 to enhance immune recognition and destruction of remaining tumor cells. Used for Advanced or metastatic non-small cell lung cancer, Other solid tumors (specific indications depend on chemotherapy backbone used).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}